Sharemaestro Newsreel

Die Sanofi-Aktie legt nach starken Q2-2026-Zahlen und erhöhter Prognose zu

Ottobock hebt Prognose für 2026 an – Aktie legt nach starken Quartalszahlen um 3 % zu

Valneva GAAP EPS of -€0.35, revenue of €65.84M; reaffirms FY 2026

* Valneva press release [https://seekingalpha.com/pr/20617691-valneva-reports-half-year-2026-financial-results-and-provides-corporate-updates] (VALN [https://seekingalpha.com/symbol/VALN]): 1H GAAP EPS of -€0.35. * Revenue of €65.84M (-32.5% Y/Y). * Solid cash position of €121.5 million as of end June 2026. * FINANCIAL OUTLOOK * Despite the continued adverse impact of the geopolitical environment on …

Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...

This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, compared to $14.2 million in Q2 2025, primarily due to prior collaboration …

Valneva Reports Half Year 2026 Financial Results and Provides Corporate Updates

VALNEVA SE Total product sales of €64.0 million In-line with expectations; full-year guidance of €135 -150 million reaffirmed Solid cash position of €121.5 million as of end June 2026 Reflects disciplined cash management and proceeds from the recent reserved offering1 Restructuring program implemented with …

Jim Cramer’s Surprise AI Pick: Aramark (ARMK)

Jim Cramer has spent months tracking the expanding ripple effects of the artificial intelligence infrastructure boom. He has repeatedly pointed out how secondary beneficiaries are emerging in unexpected places. The theme took center stage when he highlighted Aramark (NYSE:ARMK) after the food services and …

5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call

5 Must-Read Analyst Questions From Gilead Sciences's Q2 Earnings Call Gilead Sciences delivered a solid Q2, with year-over-year sales growth led by strong demand in its HIV franchise, particularly Biktarvy and the PrEP segment, as well as advances in oncology and liver disease. Management …

5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call

5 Insightful Analyst Questions From Pfizer's Q2 Earnings Call Pfizer's second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company's performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions …

Will Strong Q2 2026 Results and New Cardiac Test Change IDEXX Laboratories' (IDXX) Narrative?

IDEXX Laboratories recently reported past second-quarter 2026 results showing higher revenue and earnings, and slightly raised its full-year 2026 guidance for revenue, operating margin and EPS. The company also introduced the Catalyst proBNP Test, the first dual-species, in-clinic NT-proBNP cardiac test, expanding its connected …

CEZ AS (XPRA:CEZ) (Q2 2026) Earnings Call Highlights: Net Income Rises 10% as Windfall Tax ...

This article first appeared on GuruFocus. Revenue: Operating revenue decreased 5% year-on-year, primarily due to lower power prices. EBITDA: Down 20% to CZK59 billion, impacted by lower generation prices and reduced trading profits. Net Income: Increased 10% to CZK18.1 billion, driven by the absence …

GFT Technologies SE (WBO:GFT) (H1 2026) Earnings Call Highlights: AI-Driven Growth and ...

This article first appeared on GuruFocus. Revenue: EUR462.6 million in H1 2026, a 5% increase in both euros and constant currencies. Adjusted EBIT: EUR33 million, up 8% year-over-year, with a margin of 7.1% compared to 6.8% in H1 2025. EBT: EUR24 million, up 26% …

BeOne Medicines Ltd (ONC) (Q2 2026) Earnings Call Highlights: Revenue Surges 30% to $1. ...

This article first appeared on GuruFocus. Total Revenue: $1.7 billion, representing 30% growth year over year. GAAP Earnings per ADS: $2.05, up 144% compared to the prior year. BRUKINSA Global Revenue: Over $1.2 billion, representing 31% year-over-year growth. US BRUKINSA Sales: $893 million, representing …

VERTEX PHARMACEUTICALS AKTIE: AI-Analysen, Prognose & Kursziel

Stronger Q2 Results And New Supply Deal Might Change The Case For Investing In LivaNova (LIVN)

LivaNova PLC recently reported second-quarter 2026 results showing sales rising to US$390.59 million and net income climbing to US$108.57 million, alongside higher earnings per share versus a year earlier. On the back of this performance, the company raised its 2026 constant-currency revenue growth guidance …

LivaNova (LIVN) Could Be 5% Undervalued Following Raised 2026 Guidance

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. LivaNova (LIVN) raised its full year 2026 revenue and earnings guidance after reporting record …

Intuitive Surgical (ISRG) Beats On Q2 As Investors Ask If The Bull Case Is Priced In

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Intuitive Surgical (ISRG) shook investors after reporting strong Q2 2026 revenue and earnings that beat expectations, while revealing slower U.S. procedure growth and …

Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health …

ABBOTT LABORATORIES AKTIE: AI-Analysen, Prognose & Kursziel

Is DXCM Stock Worth Buying as Growth Improves but Valuation Stretches?

DexCom, Inc. DXCM is entering the second half of 2026 with healthier margins, broader reimbursement and a larger continuous glucose monitoring opportunity. The investment question is whether that improving setup is enough to justify a premium valuation. Growth catalysts remain visible across U.S. coverage, …

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

Bristol Myers Squibb BMY is navigating a revenue mix shift as growth products portfolio now assumes a larger role in the business, helping mitigate the impact of declining sales from mature products facing generics. The growth portfolio — including Opdivo, Opdivo Qvantig, Orencia, Yervoy, …

DXCM Stock Up Nearly 35% YTD: Will the Uptrend Continue in the Rest of 2026?

DexCom DXCM stock has rebounded sharply in 2026, gaining 34.8% after falling 14.7% in 2025, as investors increasingly recognize the company's improving growth profile and expanding continuous glucose monitoring (CGM) opportunity. The company's share price performance so far this year has outperformed the industry's …

ISRG's US Procedure Growth Slows: Is ACA Headwind a Temporary Concern?

Intuitive Surgical ISRG has faced a moderation in U.S. procedure growth during the first half of 2026, but management's commentary suggests the slowdown is more likely a temporary demand-timing issue than evidence of a structural deterioration. U.S. da Vinci procedures grew 12% in the …

Can DexCom's Raised 2026 Outlook Sustain Stronger Margin Momentum?

DexCom, Inc. DXCM raised its 2026 revenue and margin outlook after a stronger second quarter, shifting more attention toward profitability. The question is whether better gross margin and operating leverage can persist as organic growth improves. The guidance increase is encouraging, but foreign exchange, …

DXCM Rallies 52.5% in 3 Months. Can the Stock Keep Climbing From Here?

DexCom, Inc. DXCM shares have climbed 52.5% in the past three months, a sharp re-rating that raises the standard for further gains. The next leg depends less on momentum alone and more on whether earnings growth, margin expansion and new-market access can keep pace …

Can UNH's Lower Medical Costs Sustain the Earnings Recovery?

UnitedHealth Group Incorporated's UNH second-quarter results show that its earnings performance is improving. The medical care ratio (MCR) fell to 86.7% from 89.4% a year ago, meaning the company spent less of its premium revenues on medical care and retained more for profits. This …

Tigo Energy downgraded at Roth after weak revenue guidance

[Aerial view of large electrical power plant with many rows of solar photovoltaic panels for producing clean ecological electric energy in morning. Renewable electricity with zero emission concept.] Bilanol/iStock via Getty Images Tigo Energy (TYGO [https://seekingalpha.com/symbol/TYGO]) down 5.2% in Wednesday's trading as Roth Capital …

Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Gilead Sciences (NasdaqGS:GILD) announced a partnership with Nucleai to use AI-powered tissue analytics in its global antibody drug conjugate programs. The collaboration focuses …

Sandbox VR Continues to Expand with its First North Carolina Venue in Winston-Salem, Opening August 14

Sandbox VR brings the 'best virtual reality experience on the planet' to Downtown Winston-Salem WINSTON-SALEM, N.C., Aug. 12, 2026 /PRNewswire/ -- Sandbox VR, the world's premier venue for virtual reality experiences, is set to open its first North Carolina location on August 14, 2026. …

[Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Whey Protein Market size & share revenue was valued at approximately USD 12.58 Billion in 2024 and is expected to reach …

Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market

This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 …

Eli Lilly Stock Falls While Retatrutide Lawsuits Expand

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase …

Two Years Of Growth Barely Change What You Pay For Intuitive Surgical

Photo by 127071 on Pixabay Consensus growth takes only a modest slice off the multiple, and the company has not yet set the instrument pricing that lands inside those two years. Intuitive Surgical (ISRG) trades at about $401.23, roughly 32% below its 52-week high …

Absci (ABSI) On Early ABS 201 Data And Lilly Deal That Could Support Its Valuation

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development …

Is Labcorp Holdings (LH) Fully Priced Following Oncology Approvals And Raised Outlook?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Labcorp Holdings (LH) is in focus after a series of oncology diagnostics approvals and launches, including the PGDx elio tissue complete CDx for advanced …

Lilly Targets Black-Market Retatrutide Sellers

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide. Warning! GuruFocus has detected 8 Warning Sign with JPM. Is LLY …

CVS Health (CVS) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Executive Vice President of Capital Markets - Larry McGrath Chair and Chief Executive Officer - David Joyner Chief Financial Officer - Brian Newman Full Conference Call Transcript Operator: …